21 / 80
Omalizumab Response Profile and Management
J Investig Allergol Clin Immunol 2019; Vol. 29(5): 338-348
© 2019 Esmon Publicidad
doi: 10.18176/jiaci.0323
chronic urticaria: a retrospective clinical analysis. J Dermatol
Sci. 2014;73:57-62.
55. Har D, Patel S, Khan DA. Outcomes of using omalizumab for
more than 1 year in refractory chronic urticaria. Ann Allergy
Asthma Immunol. 2015;115:126-9.
56. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al.
Omalizumab for the treatment of chronic spontaneous
urticaria: A meta-analysis of randomized clinical trials. J
Allergy Clin Immunol. 2016;137:1742-50.e4.
57. Kasperska-Zajac A, Jarz
ą
b J,
Ż
erdzi
ń
ska A, B
ą
k K, Grzanka A.
Effective treatment of different phenotypes of chronic urticaria
with omalizumab: Case reports and review of literature. Int J
Immunopathol Pharmacol. 2016;29:320-8.
58. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A,
et al. A randomized, placebo-controlled, doseranging study of
single-dose omalizumab in patients with H1-antihistamine-
refractory chronic idiopathic urticaria. J Allergy Clin Immunol.
2011;128:567-73.e1.
59. Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M,
et al. Real-life effectiveness of omalizumab in severe allergic
asthma above the recommended dosing range criteria. Clin
Exp Allergy. 2016;46:1407-15.
348
Manuscript received May 29, 2018; accepted for
publication September 10, 2018.
Ana María Giménez Arnau
Dermatology Department
Hospital del Mar
Passeig Maritim 25-26b
08003 Barcelona, Spain
E-mail:
anamariagimenezarnau@gmail.com60. Uysal P, Eller E, Mortz CG, Bindslev-Jensen C. An algorithm
for treating chronic urticaria with omalizumab: dose
interval should be individualized. J Allergy Clin Immunol.
2014;133:914-5.e2.